Lewis Saul & Associates, P.C. is actively representing families from throughout Maine and the rest of the United States with children who were born with birth defects after their mothers used Zofran (ondansetron) during pregnancy. For over a decade, GlaxoSmithKline (GSK) promoted Zofran “off-label” for the treatment of nausea and vomiting during pregnancy when the drug has never been approved for this use. Throughout this time, GSK had evidence that Zofran was linked to congenital birth defects but ignored the data in order to continue to reap billions of dollars in illegal sales of the drug to pregnant women. Medical research indicates that children born to mothers who used Zofran during pregnancy are at increased risk of suffering atrial septal defect (a hole between the upper chambers of the heart), ventricular septal defect (a hole between the left and right ventricles of the heart), cleft palate (a split in the roof of the mouth), cleft lip (a split or separation of the two side of the upper lip) and other congenital birth defects. Unlike other anti-nausea medications, GSK never conducted a single study on the effects of Zofran on pregnant women or children in utero. Additionally, GSK has never warned physicians or patients in the drug’s prescribing information or promotional materials that Zofran should not be used during pregnancy due to the risk of birth defects. If you or a loved one used Zofran during pregnancy and gave birth to a child with a birth defect, you may be entitled to pursue a claim against the manufacturers for damages. For a free and confidential case evaluation, please call our office toll-free at (888) 747-5342 or complete our online contact form and we will promptly respond to your inquiry.